已收盘 06-27 16:00:00 美东时间
0.000
0.00%
Quanterix (QTRX) reported Q2 2026 revenue of $32.9 million, up 34% year over year, while GAAP diluted loss per share widened to $1.04 from $0.77. GAAP gross margin slipped to 38.5%, but the adjusted EBITDA loss narrowed to $10.0 million from $13.7 million. A $26.9 million Akoya-related goodwill impairment weighed on reported earnings. Management cited execution challenges and continued market softness, lowered 2026 revenue guidance to $142 millio
08-10 12:13
Quanterix Corporation (QTRX) added ~3% in the premarket on Wednesday after announcing that its Alzheimer’s test, LucentAD Complete, will be covered by Elevance Health’s (ELV) Anthem Blue Cross and Blu...
07-15 20:39
https://apnews.com/article/iran-us-israel-war-2-june-2026-9bde9a3425d4b9ff70f157bdae0fb982?taid=6a1ee28bba61b20001693b1e&utm_campaign=TrueAnthem&utm_medium=AP&utm_source=Twitter
06-02 22:08
Elutia (NASDAQ:ELUT) released first-quarter financial results and hosted an ear...
05-15 05:55
https://apnews.com/article/congress-louisiana-primaries-supreme-court-03cdb6951d7fefb448bfd2f37f98c0ea?utm_campaign=trueAnthem%3A+New+Content+%28Feed%29&utm_medium=trueAnthem&utm_source=twitter
04-30 22:27
Axogen (NASDAQ:AXGN) released first-quarter financial results and hosted an ear...
04-28 22:18
https://apnews.com/live/iran-war-israel-trump-03-19-2026?taid=69bbb66dfec6580001a7ec61&utm_campaign=TrueAnthem&utm_medium=AP&utm_source=Twitter#0000019d-0535-d813-afbd-4ffd71c20000
03-19 17:25
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has
03-10 04:16
Abeona Therapeutics has announced progress in the commercial launch of ZEVASKYN, a first-of-its-kind gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). Following optimization of a release assay in 2025, the therapy resumed manufacturing in late 2026, with multiple biopsies collected and treatments completed. ZEVASKYN has secured broad payer coverage, including Medicaid and Medicare, with CMS assig...
03-09 11:30